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neonatal hypoglycaemia 53%, foetal loss 11%, preterm deliv-
ery 22%, obstetric complications 33%, congenital malforma-
tions 5%, birth weight >4000 g 20%, and other adverse events
12%. The mean inpatient cost per subject was 4589
(SD  3961). The main costs were admission for pre-term
infants (3089, SD  3508), adverse events and obstetric com-
plications (532, SD  839), and normal delivery costs (968,
SD  328). The mean cost was around four times the average
cost of delivery in a UK hospital (1078). In England and
Wales around 5250 women with type 1 diabetes give birth
every year. The excess cost of these births to the NHS is around
18.4 million per annum. CONCLUSION: Inpatient costs
are high in pregnant women with type 1 diabetes. Successful
intervention in this group could improve health outcomes and
substantially reduce cost.
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OBJECTIVES: Hemoglobin A1c (HbA1c), a clinical measure of
ambient blood glucose concentrations over the previous 3
month time period, is recognized as a surrogate measure for
the risk of complications among patients with diabetes. The
purpose of this research is to quantify the impact of changes
in glycemic control on diabetes-related medical costs.
METHODS: Data from the i3 LabRx Database were used for
this study. Individuals were included in the analysis if they had
two diagnoses of type 2 diabetes (ﬁrst diagnosis identiﬁed as
the index date), had one valid HbA1c test result recorded in the
six months prior to the index date and had at least one valid
HbA1c test result recorded in the twelve months post index
date (N = 2,239). Multivariate regressions were used to
examine the relationship between the change in HbA1c from
the post-period to the pre-period on diabetes related costs,
while controlling for patient characteristics, general health
status, comorbidities, timing between the post and pre-period
HbA1c tests, and initial value of HbA1c. RESULTS: Thirty
percent of the individuals in this sample were found to have an
initial HbA1c value greater than 7. Results from the multivari-
ate analyses indicate that after controlling for other factors
which may impact diabetes-related costs, a one point reduction
in HbA1c value was associated with a $433 reduction in total
one-year diabetes-related medical costs (p = 0.0033). In addi-
tion, a one point reduction in HbA1c value was also associated
with a signiﬁcant reduction in diabetes-related outpatient
costs (-$127, p = 0.0268) as well as a signiﬁcant reduction in
diabetes-related outpatient prescription drug costs (-$293,
p < 0.0001). CONCLUSION: Evidence from this analysis indi-
cates that the direct medical costs of treating type 2 diabetes
are signiﬁcantly reduced as HbA1c values are reduced. These
results highlight that there are savings associated with a one
point reduction in patients’ glycemic control.
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OBJECTIVES: The aim of this study was to estimate the cost-
utility of type 1 diabetes patients treated with detemir based
basal-bolus therapy versus neutral protamine Hagedorn (NPH)
insulin based basal-bolus therapy in France using results
obtained from a meta-analyses of three clinical trials. The meta-
analyses demonstrated a short-term improvement for detemir
over NPH in HbA1c (0.13% points lower), a decrease in
hypoglycemic events (by 4%) and lower body mass index (BMI)
(0.21 kg.m-2). METHODS: A published, validated, peer-
reviewed computer simulation model of diabetes (the CORE
Diabetes Model) was used to project short-term results obtained
from the ﬁxed-effects meta-analysis to long-term clinical and cost
outcomes (including life quality adjusted life expectancy, inci-
dence of complications, and direct medical costs), when basal
detemir or NPH is used in combination with either insulin aspart
or human soluble insulin. Probabilities of complications were
derived from landmark clinical and epidemiological studies.
The costs of treating complications and appropriate baseline
comorbidities were retrieved from published sources and France
speciﬁc mortality rates applied. Total direct medical costs
(complications + treatment costs) were projected over patient
lifetimes, and future costs and clinical beneﬁts discounted at 3%
per annum. RESULTS: Therapeutic beneﬁts of superior glycemic
control, lower hypoglycemic event rates and reduced BMI asso-
ciated with detemir based basal-bolus therapy led an increase in
quality-adjusted life expectancy of 0.190 years (7.38  0.09
versus 7.18  0.09) versus NPH. Increased total lifetime costs/
patient of €2,370 (€75,477  2109 versus €73,106  2165)
with detemir resulted in an incremental cost-effectiveness ratio of
€12,477 per quality-adjusted life year (QALYs) gained. CON-
CLUSION: Therapeutic improvements demonstrated in the
meta-analyses of detemir can be reasonably expected to lead to
decreases in long-term complications, improvements in quality-
adjusted life expectancy and a cost-effectiveness ratio which falls
well below a range considered to represent good value for money
(<€50,000/QALY gained).
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OBJECTIVES: To evaluate long-term economic outcomes in the
Swedish setting for type 2 diabetes patients treated with either
mealtime insulin aspart (IAsp, NovoRapid) or human insulin
(HI) as part of basal-bolus therapy, based on ﬁndings from the
European PREDICTIVE study (Predictable Results and Experi-
ence in Diabetes through Intensiﬁcation and Control to Target:
an International Variability Evaluation). METHODS: The
CORE Diabetes Model, a published and validated computer
simulation model was used to project long-term outcomes and
account lifetime costs for patients receiving either IAsp or HI.
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